RxDoctor Payments Data

Donna Evans, NP

Nurse Practitioner · Conway, SCNPI 1942317037

Payments from drug & device makers

$1,338in general payments, 2019–2025

Across 19 payments — averaging $70.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$262
  • Calliditas Therapeutics US Inc.$237
  • Vifor Pharma, Inc.$207
  • Travere Therapeutics, Inc.$147
  • GSK$123
  • Bayer$101
  • plus $260 from 6 others

What the payments were for

  • Food & beverage$1,338100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,338 in reported general payments places this provider in the 80th percentile of 1,346 nurse practitioner providers in South Carolina.

See all nurse practitioner providers in South Carolina

Medicare billing

Part B allowed, 2024
$95,075
Medicare patients
359
Services billed
613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol116$101,887
JardianceEmpagliflozin95$93,603
KerendiaFinerenone43$43,132
AuryxiaFerric Citrate11$30,298
EntrestoSacubitril/Valsartan27$27,660
GlyxambiEmpagliflozin/Linagliptin16$18,862
MounjaroTirzepatide13$13,263
Sevelamer Carbonate17$4,513
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid15$1,962
Calcitriol41$1,056
Losartan Potassium104$1,027
Cinacalcet Hcl16$936
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril39$855
Allopurinol46$606
Lisinopril73$589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$262$101,887116 claims
BayerKerendia$101$43,13243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,346 nurse practitioner providers in South Carolina.

Other nurse practitioner in Conway

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →